WallStSmart

Molecular Partners AG ADR (MOLN)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MOLN leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

MOLN

Avoid

19

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -3.04

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MOLN.

MRNAUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$134.69

Current Price

$154.04

$19.35 discount

UndervaluedFair: $134.69Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MOLN2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

MOLN4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$150.16M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
9.1x4/10

Trading at 9.1x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MOLN

The strongest argument for MOLN centers on Debt/Equity, Price/Book.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : MOLN

The primary concerns for MOLN are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

MOLN profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

MRNA carries more volatility with a beta of 1.11 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

MOLN generates stronger free cash flow (-11M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Molecular Partners AG ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?